While many academic and industrial laboratories are pursuing research on the fundamental genetics of neurodegenerative diseases, there is a growing interest in how the immune system interacts with the nervous system and how certain immune cells can be modulated to slow down or even reverse the ravages of diseases such as ALS, Alzheimer’s, Parkinson’s, and Frontotemporal Dementia. This talk will focus on the role of the immune system in neurological disorders and the efforts Neuraltus Pharmaceuticals is undertaking to develop NP001, a small molecule modulator of immune function, for the treatment of ALS (Lou Gehrig’s Disease).
About the Speaker:
Rich Casey has spent his entire 40-year career in the pharmaceutical and biotechnology industries. He is currently CEO of Neuraltus Pharmaceuticals, which is developing a drug for ALS (Lou Gehrig’s Disease). For eleven years, he was Chairman and CEO of Scios, Inc., a biotech company in the areas of cardiovascular disease and inflammation. Under his leadership, Scios successfully developed Natrecor (nesiritide), a leading treatment for acute congestive heart failure. Scios was sold in 2003 to Johnson & Johnson.
Earlier in his career, Rich worked in a variety of marketing, sales, and general management positions at Eli Lilly, Syntex, and Alza. He received both his BS degree (Chemistry, 1968) and his MBA (1973) from Stanford University. From 1968 to 1970, Rich served in the Peace Corps in Ethiopia as a producer and writer of science and mathematics programs for educational television.
Title images are licensed under Creative Commons License.